Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30574285 | 0.88 | KCNH2 (0.36) | KCNH2KDM4EALDH1A1HSD17B10MAPK1 | |
| SCHEMBL1838368 | 0.88 | KCNH2 (0.36) | KCNH2KDM4EALDH1A1HSD17B10MAPK1 | |
| SCHEMBL2154131 | 0.83 | KCNH2 (0.32) | CYP3A4TDP1KCNH2KDM4EALDH1A1 | |
| SCHEMBL2155672 | 0.81 | ALDH1A1 (0.33) | TDP1KCNH2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL1840267 | 0.81 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2KCNH2 | |
| SCHEMBL27970886 | 0.79 | RIPK1 (0.30) | RIPK1 | |
| SCHEMBL2153874 | 0.78 | KCNH2 (0.35) | KCNH2KDM4EALDH1A1HSD17B10CA12 | |
| SCHEMBL476857 | 0.78 | CA1 (0.50) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL30992110 | 0.78 | CA1 (0.50) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL8459532 | 0.76 | CA1 (0.48) | CYP3A4TDP1DRD1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0294000-A2 | Novel diaryl phosphides | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1988-12-07 | — | — | EP | claimed |
| EP-2321244-B1 | IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-8558030-B2 | Process for telomerization of butadiene | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20110137086-A1 | PROCESS FOR TELOMERIZATION OF BUTADIENE | Dow Global Technologies LLC (Formerly known as Dow Global Technologies Inc.) (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2321244-A2 | AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE | Dow Global Technologies LLC (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010019360-A2 | AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| EP-0294000-A2 | Novel diaryl phosphides | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1988-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137086-A1 | PROCESS FOR TELOMERIZATION OF BUTADIENE | HRH3, HRH4, TELO2 | CYP3A4 1711/4885TDP1 646/4885DRD1 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.